News Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-20 EDT			5-day change	1st Jan Change
55.25 ^USD	-2.23%		+4.13%	+25.43%

08-10	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-10	Novo Nordisk works to address FDA's findings at Indiana plant	FW

All News

Mentions Relevance

08-14	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
08-10	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-07	Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug	RE
08-07	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag	DJ
08-07	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-07	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date	BU
08-06	Scholar Rock Holding Corporation, Q2 2026 Earnings Call, Aug 06, 2026
08-06	Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Scholar Rock Q2 Net Loss Narrows	MT
08-06	Scholar Rock Reports Apitegromab Biologics License Application Progress, Initiates Phase 2 Forge Study, and Provides Updates on Srk-439 and Opal Trials	CI
08-06	Earnings Flash (SRRK) Scholar Rock Posts Q2 Loss of $0.84 a Share, vs. FactSet Est of $0.84 Loss	MT
08-06	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights	BU
07-29	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference	BU
07-20	Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026	RE
07-20	Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)	BU
07-17	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
07-16	Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026	BU
06-22	Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD	BU
06-12	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
06-09	Scholar Rock Holding Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:00 AM
05-26	Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	BU
05-20	Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference	BU
05-15	Scholar Rock reports new employee inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
05-15	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
05-12	Scholar Rock Holding Corporation Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08:00 AM